for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SMA Solar Technology AG

S92G.DE

Latest Trade

42.48EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

24.68

 - 

71.80

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
42.48
Open
--
Volume
--
3M AVG Volume
3.07
Today's High
--
Today's Low
--
52 Week High
71.80
52 Week Low
24.68
Shares Out (MIL)
34.70
Market Cap (MIL)
1,483.08
Forward P/E
49.81
Dividend (Yield %)
0.70

Next Event

Half Year 2021 SMA Solar Technology AG Earnings Release

Latest Developments

More

SMA Solar Affirms 2021 Guidance after Q1 Earnings Jump

SMA Solar FY Net Loss Turns To Profit Of EUR 28.1 Million

SMA Solar Technology FY EBITDA At About EUR 72 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SMA Solar Technology AG

SMA Solar Technology AG is a Germany-based developer of photovoltaic (PV) system technology. The Company operates through five segments: Residential, Commercial, Utility, Off-Grid and Storage and Service. The Residential segment focuses on small PV systems for private applications with micro and string inverters, energy management solutions, storage systems and communication products and accessories. The Commercial segment provides three-phase string inverters, energy management solutions, medium-voltage technology and other accessories. The Utility segment specializes in large-scale PV power plants with central inverters, and also provides grid services. The Off-Grid and Storage segment offers system technology for the integration of different battery technologies and power classes and collaborates with battery manufacturers and companies in the automotive industry. The Service segment comprises service and maintenance, operational management and the spare parts business.

Industry

Semiconductors

Contact Info

Sonnenallee 1

34266

Germany

+49.561.95220

https://www.sma.de/

Executive Leadership

Uwe Kleinkauf

Chairman of the Supervisory Board

Juergen Reinert

Chief Executive Officer, Chief Operating Officer, Chief Technology Officer, Member of the Management Board

Kim Fausing

Deputy Chairman of the Supervisory Board, Shareholder Representative

Ulrich Hadding

Chief Financial, Human Resources and Legal Officer

Alexa Hergenroether

Independent Member of the Supervisory Board, Shareholder Representative

Key Stats

2.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

0.8K

2019

0.9K

2020

1.0K

2021(E)

1.1K
EPS (EUR)

2018

-4.210

2019

-0.250

2020

0.810

2021(E)

0.858
Price To Earnings (TTM)
40.78
Price To Sales (TTM)
1.51
Price To Book (MRQ)
3.30
Price To Cash Flow (TTM)
18.66
Total Debt To Equity (MRQ)
9.25
LT Debt To Equity (MRQ)
6.46
Return on Investment (TTM)
--
Return on Equity (TTM)
6.08

Latest News

Latest News

BRIEF-Vaxxel Acquires Transgene's DuckCelt-T17 Cell Line

* VAXXEL ACQUIRES TRANSGENE'S DUCKCELT®-T17 CELL LINE TO DEVELOP INDUSTRIAL-SCALE VACCINES AGAINST RESPIRATORY VIRUSES

Roche's SMA drug trial win bolsters $2 billion sales prospects

Roche's spinal muscular atrophy (SMA) drug risdiplam hit another clinical trial target, the Swiss drugmaker said on Thursday, which analysts said bolsters its prospects of reaching $2 billion in annual sales.

SMA Solar CEO steps down, to be replaced by deputy

SMA Solar, Germany's largest solar group, on Monday named Juergen Reinert, deputy chief executive and board member for operations and technology, as its new CEO, replacing Pierre-Pascal Urbon, who is leaving after seven years at the helm.

UPDATE 1-SMA Solar shares plunge to 1-yr low on China woes

* Shares fall to lowest level since late-July 2017 (Recasts, adds shares, context)

SMA Solar expects chips shortage to ease in H2

SMA Solar, Germany's largest solar company, on Thursday said it expected a shortage of chips needed for the production of solar inverters to ease in the second half of the year, which the company said would lead to higher sales.

Roche SMA drug shines in study as costly new therapies advance

A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up